CDK-IN-10

CAS No. 660822-84-4

CDK-IN-10( —— )

Catalog No. M35483 CAS No. 660822-84-4

CDK-IN-10 is a cell cycle protein-dependent kinase (CDK) inhibitor with potential anticancer activity for cancer research.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 193 In Stock
10MG 276 In Stock
25MG 430 In Stock
50MG 581 In Stock
100MG 768 In Stock
200MG 1032 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CDK-IN-10
  • Note
    Research use only, not for human use.
  • Brief Description
    CDK-IN-10 is a cell cycle protein-dependent kinase (CDK) inhibitor with potential anticancer activity for cancer research.
  • Description
    CDK-IN-10 (example 54) is a cyclin dependent kinase (CDK) inhibitor that can be used in cancer research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    660822-84-4
  • Formula Weight
    322.36
  • Molecular Formula
    C18H18N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(NC1=CC=C(C=C1)N2CCOCC2)(=O)C=3C=4C(NN3)=CC=CC4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Valerio Berdini, et al. 1h-indazole-3-carboxamide compounds as cyclin dependent kinases (cdk) inhibitors. WO2004014864
molnova catalog
related products
  • FIT-039

    FIT-039 is a potent, selective CDK9 inhibitor with IC50 of 5.8 uM for CKD9/cyclin T1, suppresses the replication of HSV-1 (IC50=0.69 uM)

  • ICEC 0942 hydrochlor...

    ICEC 0942 (CT7001) is a potent, selective, orally active CDK7 inhibitor with IC50 of 41 nM, displays 15-fold selectivity over CDK2 (IC50=578 nM).

  • CDK9-IN-15

    CDK9-IN-15 is a potent small molecule CDK9 inhibitor, which can block the phosphorylation of positive transcription elongation factor b (P-TEFb) on the C-terminal region of RNA Poly-II by degradation and inhibition of CDK9, inhibit transcription, and rapidly reduce the level of intracellular mRNA, thereby causing apoptosis of tumor cells.